奥美沙坦治疗原发性高血压临床疗效分析

Analysis on the clinical efficacy of olmesartan in the treatment of patients with essential hypertension

目的:探究奥美沙坦治疗原发性高血压患者的临床疗效。方法:选取某院2011年2月-2012年2月之间收治的100例首次确诊的原发性高血压患者给予奥美沙坦治疗,为观察组。并与同期健康的100名志愿者为对照组,不给予任何治疗。结果:观察组的患者治疗后血压较治疗前有明显的改善(P<0.05),接近正常对照组的情况(P>0.05)。而且治疗前后心率比较无明显的差异(P>0.05);观察组患者治疗后ADMA和ET-1以及FMD较治疗前有明显的改善(P<0.05),与对照组比较差异无显著性(P>0.05);而观察组治疗后的NO、8-iso-PGF2α、hs-CRP及NMD较治疗前比较无明显的差异(P>0.05)。结论:奥美沙坦能够有效地降低血压而达到治疗原发性高血压的目的,其改善FMD作用可能与其降低血浆中的ADMA和ET-1含量有关。

OBJECTIVE To explore the efficacy of olmesartan treatment in patients with essential hypertension. METHODS From February 2011 to February 2012,100 cases of essential hypertension patients diagnosed at the first time were enrolled as the observation group,they all received the olmesartan treatment. And 100 healthy objects taken as the control group, were not given any treatment. RESULTS The blood pressure level of the observation group was significantly improvement compared with before（P〈20. 05）, which was close to the normal control group（P^0. 05） . But there was no obvious difference before and after treatment on the heart rate （P〉0. 05）. The ADMA ,ET-1 and FMD of the observation group were all significantly im- proved after treatment compared with those before treatment , and no significant difference compared with the control group （P 〉0.05）. There was no significant difference on the NO, 8 iso-PGF2α, hs-CRP and NMD in the observation group compared with before treatment and with the control group（P〉0.05）. CONCLUSION Olmesartan can effectively lower blood pressure of essential hypertension to reach the purpose of the treatment , the improvement of FMD role may be related to the reduction of plasma ADMA and ET-1 levels.